Expression of BAP1 and ATM proteins: Association with AJCC tumor category in uveal melanoma.
Adolescent
Adult
Aged
Aged, 80 and over
Ataxia Telangiectasia Mutated Proteins
/ biosynthesis
Biomarkers, Tumor
/ genetics
DNA Mutational Analysis
Female
Humans
Male
Melanoma
/ genetics
Middle Aged
Tumor Suppressor Proteins
/ biosynthesis
Ubiquitin Thiolesterase
/ biosynthesis
Uveal Neoplasms
/ genetics
Young Adult
AJCC tumor category
ATM
BAP1
Co-expression
Immunohistochemistry
Uveal Melanoma
Journal
Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
01
11
2019
accepted:
08
11
2019
pubmed:
22
12
2019
medline:
18
11
2020
entrez:
22
12
2019
Statut:
ppublish
Résumé
Our aim is to detect the association of BAP1 with ATM protein with AJCC tumor category and its prognostic significance. Based on AJCC tumor category, 69 patients samples were categorized into group A (LBD > 15 mm & tumor thickness ≥ 8 mm) and group B (LBD ≤ 15 mm & tumor thickness < 8 mm) subjected to immunohistochemistry to assess the nuclear expression of ATM and BAP1 proteins. Mutational analysis of BAP1 was performed on five samples from each group. Group A tumors showed insertion mutation of BAP1 gene while there was no mutation seen in group B tumor. At translational level loss of ATM and BAP1 was found in 65% and 66% of cases respectively. Loss of ATM with BAP1 was seen in 55% of cases which was more frequent in group A which was statically significant with metastasis (p = 0.006), advanced tumor staging (p = 0.021) and reduced metastasis-free survival (p = 0.048). On multivariate analysis loss of ATM along with BAP1 came out to be an independent prognostic marker (p = 0.035). Our data suggest that loss of BAP1 along with ATM might serve as a potential prognostic indicator in patients with an advanced AJCC tumor category, which leads to an increased risk of metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
Our aim is to detect the association of BAP1 with ATM protein with AJCC tumor category and its prognostic significance.
METHODS
METHODS
Based on AJCC tumor category, 69 patients samples were categorized into group A (LBD > 15 mm & tumor thickness ≥ 8 mm) and group B (LBD ≤ 15 mm & tumor thickness < 8 mm) subjected to immunohistochemistry to assess the nuclear expression of ATM and BAP1 proteins. Mutational analysis of BAP1 was performed on five samples from each group.
RESULTS
RESULTS
Group A tumors showed insertion mutation of BAP1 gene while there was no mutation seen in group B tumor. At translational level loss of ATM and BAP1 was found in 65% and 66% of cases respectively. Loss of ATM with BAP1 was seen in 55% of cases which was more frequent in group A which was statically significant with metastasis (p = 0.006), advanced tumor staging (p = 0.021) and reduced metastasis-free survival (p = 0.048). On multivariate analysis loss of ATM along with BAP1 came out to be an independent prognostic marker (p = 0.035).
CONCLUSION
CONCLUSIONS
Our data suggest that loss of BAP1 along with ATM might serve as a potential prognostic indicator in patients with an advanced AJCC tumor category, which leads to an increased risk of metastasis.
Identifiants
pubmed: 31864162
pii: S1092-9134(19)30361-2
doi: 10.1016/j.anndiagpath.2019.151432
pii:
doi:
Substances chimiques
BAP1 protein, human
0
Biomarkers, Tumor
0
Tumor Suppressor Proteins
0
ATM protein, human
EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
Ubiquitin Thiolesterase
EC 3.4.19.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151432Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.